These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1412 related articles for article (PubMed ID: 27516446)

  • 21. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
    Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M
    Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
    Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine Tumor Diagnosis and Management:
    Sanli Y; Garg I; Kandathil A; Kendi T; Zanetti MJB; Kuyumcu S; Subramaniam RM
    AJR Am J Roentgenol; 2018 Aug; 211(2):267-277. PubMed ID: 29975116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inferior performance of [
    Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [
    Chan DL; Hayes AR; Karfis I; Conner A; Mileva M; Bernard E; Schembri G; Navalkissoor S; Gnanasegaran G; Pavlakis N; Marin C; Vanderlinden B; Flamen P; Roach P; Caplin ME; Toumpanakis C; Bailey DL
    J Nucl Med; 2024 Feb; 65(2):185-191. PubMed ID: 38164579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
    Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
    Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
    Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
    Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas.
    Ambrosini V; Campana D; Polverari G; Peterle C; Diodato S; Ricci C; Allegri V; Casadei R; Tomassetti P; Fanti S
    J Nucl Med; 2015 Dec; 56(12):1843-8. PubMed ID: 26405169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
    Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
    Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.